BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) insider Henry J. Fuchs sold 23,011 shares of BioMarin Pharmaceutical stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $130.00, for a total transaction of $2,991,430.00. Following the completion of the sale, the insider now owns 102,995 shares in the company, valued at $13,389,350. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of BioMarin Pharmaceutical stock opened at $126.43 on Thursday. The firm has a market capitalization of $22.92 billion, a PE ratio of 207.26 and a beta of 1.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.58 and a quick ratio of 1.72. The company's fifty day moving average price is $116.33 and its two-hundred day moving average price is $94.93. BioMarin Pharmaceutical Inc. has a 52-week low of $62.88 and a 52-week high of $130.04.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.12 by $0.32. The firm had revenue of $502.07 million for the quarter, compared to analyst estimates of $468.77 million. BioMarin Pharmaceutical had a net margin of 6.31% and a return on equity of 3.62%. The business's revenue for the quarter was up 25.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.32) EPS. Analysts predict that BioMarin Pharmaceutical Inc. will post 0.43 earnings per share for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. boosted its stake in shares of BioMarin Pharmaceutical by 3.2% in the 4th quarter. Victory Capital Management Inc. now owns 120,137 shares of the biotechnology company's stock valued at $10,158,000 after purchasing an additional 3,763 shares in the last quarter. Panagora Asset Management Inc. boosted its stake in shares of BioMarin Pharmaceutical by 16.0% in the 4th quarter. Panagora Asset Management Inc. now owns 3,015 shares of the biotechnology company's stock valued at $255,000 after purchasing an additional 415 shares in the last quarter. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of BioMarin Pharmaceutical in the 4th quarter valued at $403,000. Chevy Chase Trust Holdings Inc. acquired a new stake in shares of BioMarin Pharmaceutical in the 4th quarter valued at $25,000. Finally, Toronto Dominion Bank boosted its stake in shares of BioMarin Pharmaceutical by 9.1% in the 4th quarter. Toronto Dominion Bank now owns 31,827 shares of the biotechnology company's stock valued at $2,691,000 after purchasing an additional 2,668 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts recently weighed in on BMRN shares. Credit Suisse Group reiterated a "buy" rating and issued a $128.00 price objective on shares of BioMarin Pharmaceutical in a research report on Monday, June 1st. William Blair restated a "buy" rating on shares of BioMarin Pharmaceutical in a report on Friday, May 1st. SunTrust Banks raised their price target on shares of BioMarin Pharmaceutical from $109.00 to $143.00 in a report on Thursday, June 18th. Bank of America lifted their target price on shares of BioMarin Pharmaceutical from $120.00 to $130.00 and gave the company a "buy" rating in a research note on Wednesday, June 10th. Finally, Oppenheimer lifted their target price on shares of BioMarin Pharmaceutical from $88.00 to $95.00 and gave the company a "performer" rating in a research note on Thursday, June 18th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seventeen have given a buy rating to the company. The stock has a consensus rating of "Buy" and an average price target of $118.67.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Featured Article: What is the Beige Book?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
8 Pharmaceutical Companies Working on a Coronavirus Cure
We are living through interesting times. Not an hour goes by when Americans don’t receive some reminder of the impact the coronavirus has on our lives. The race is on for an effective, FDA-approved treatment for the virus. Despite, vaccines being available for human trial in record time, we are many months away from having a viable vaccine.
However, we may be somewhat closer in finding some antiviral treatments. And if you’ve watched the market closely this week, any news on that front tends to move the market in a positive direction.
That brings up another truth of investing. There are some stocks that thrive from other stocks misery. And that’s why we’ve put together this special report. If you’re an investor who is looking to jump into this bear market, the pharmaceutical sector is a logical choice.
A combination of big-name drug companies as well as smaller startup companies are working around the clock to develop vaccines or treatments that will target the infection caused by the novel coronavirus.
View the "8 Pharmaceutical Companies Working on a Coronavirus Cure".